Status:
UNKNOWN
Efficacy and Safety of Tadalafil in Hemodialysis Patients
Lead Sponsor:
University of Pernambuco
Conditions:
Erectile Dysfunction
Eligibility:
MALE
18-70 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to check the safety and efficacy of a pde5 inhibitor, tadalafil, is a special group of patients: Renal chronic patients in hemodialysis treatment.
Detailed Description
In our country, the number of patients in hemodialysis for the treatment of renal chronic dysfunction is very huge. As we know this group has a greater prevalence of sexual dysfunction than the genera...
Eligibility Criteria
Inclusion
- Men between 18 and 70 years old
- Diagnosticated ED for 6 months at least
- Accept the protocol
- Sign the informed consent
- Renal chronic patients in hemodyalisis
Exclusion
- History of another PDE5 inhibittor use.
- C.C.I. grade III (NYHA)
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00334477
Last Update
June 7 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de Aeronautica de Recife
Recife, Pernambuco, Brazil, 50000-000